Events
| Tue | ||
|---|---|---|
The Online Seminar shows the Possibilities of the use of Desktop-Sharing Software. The Online-Seminar is free of charge an will contain the following topic. How to Setup the Software. The Webinar will held on request, the duration is approx. 30 Minutes Further Information to the Online-Seminar Start: 01/31/2012 10:00 am
This topic will focus on how health care providers can stay out of trouble. Too often health care providers concentrate on providing services and neglect any effort to avoid penalties for fraud and abuse, leaving them exposed to punitive actions. State & federal agencies which oversee healthcare programs are increasing their efforts to eliminate fraud and abuse. Resulting in close scrutiny of provider practices. Areas Covered in the Session: Price List: webinars@mentorhealth.com Phone: 800-447-9407 Start: 01/31/2012 10:00 am
End: 01/31/2012 11:30 am
The FDA has requested BLA sponsors to submit sub-visible particulate data for Well Characterized Protein Products in the clinical and commercial phases. The evidence continues to accumulate that particulates increase immunogenicity of the protein product. The regulatory requirements for testing Biologics for Particulates continue to evolve. Why Should You Attend: Proteinaceous Particulates in Biologics injectibles can arise from the aggregation of the protein product and can be induced by silicone droplets, metal particles and glass particles. Aggregates in protein products present a safety concern because they increase the immunogenicity of the product. The FDA has therefore requested BLA sponsors to present sub-visible particulate data at the clinical and commercial stage. The initially identified method –gap for suitable techniques for testing particles in the 0.2 - 10 micron range is being rapidly filled by new technologies. Whether the aggregates found during in vitro testing truly reflects the quantity and type of aggregates in vivo is not clear and continues to be debated. Nevertheless this debate has increased the scrutiny of reviewers on the testing and reporting of particulates in Protein Therapeutics. This updated webinar addresses recent discussions in the industry related to testing sub-visible particulates in Biologics injectibles. Recent FDA expectations for reporting data will be discussed. Methods for characterization and routine testing of particulates, their advantages and limitations will be discussed. Case studies where the various methods have been used for characterization of the sub-visible particles will be discussed. Areas Covered in the Seminar: - Why test for sub-visible particulates in protein therapeutics. Start: 01/31/2012 10:00 am
End: 01/31/2012 1:00 pm
This 3-hr virtual seminar on HIPAA Security Rule Compliance and Risk Analysis will present an organized and simple approach to perform an effective Information Security Risk Analysis and reduce your organization’s exposure to breaches and penalties. Examples of real situations will be presented and new procedures to reduce risks will be discussed. Why Should You Attend: This session will present the background of the regulations that call for information security risk analysis and show how it fits in to an overall information security management process. The risk analysis process will be presented within the context of the overall risk prioritization and risk mitigation process, using an example. Areas of high risk, as identified by respected industry organizations, will be identified to ensure that the most significant risks are discovered and adequately prioritized. The risk analysis process will be applied to a simplified example in order to relate the process to a real situation and drive home the usefulness of the process. Attendees will gain insights into the management of risks and reduction of exposure to breaches and penalties, and will be able to implement new procedures that will reduce risks immediately. Start: 01/31/2012 10:00 am
Short Description: Full Description: This webinar will review the current research and discuss specific ways of screening for Developmental Prosopagnosia in children with and without ASD. Empirically proven treatment methods will be discussed and specific techniques of accommodating children will be outlined. Course Includes: What You Will Learn: Your Presenter: Dr. Blake serves as a member of the American Psychological Association, International Dyslexia Association, Children and Adults with Attention Deficit Disorders, Learning Disabilities Association, and the National Attention Deficit Disorder Association and was a 1991 delegate to the National Institute for Literacy’s “LEAD 2000 Congress,” where he advised Congress on diagnostic and remediation issues. Disclaimer: Technical requirements: Who Should Attend: Start: 01/31/2012 10:00 am
End: 01/31/2012 11:00 am
This webinar will cover how to develop and implement a formal program on telecommuting for companies who are considering it and how to review and formalize current practices for companies who already have a program. Why Should You Attend: More and more companies are allowing employees to perform their work from a remote worksite ranging from an occasional occurrence to a regular full-time schedule. This webinar contains an overview of how to develop a policy, who or what positions would be eligible, alternative work arrangements, the approval process, rules of operation, compensation and eligible expenses, equipment considerations and support, and effective communication practices. We will cover the business case for telecommuting as well as the advantages and disadvantages. This session will also cover how to develop a proposal to adopt either a full telecommuting plan or hybrid and how to measure, justify and communicate results. Areas Covered in the Seminar: - Presenting the Business Case for Telecommuting. | ||
